Close
Enter your
text here

NK cells

Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD
 Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD 150 150 Katie Brind'Amour, PhD, MS, CHES
By:

Meisam Naeimi Kararoudi, DVM, PhD, director of the CRISPR/Gene Editing Core and principal investigator in the Center for Childhood Cancer Research at Nationwide Children’s, has taken a winding, international road to his current role at Nationwide Children’s Hospital. From his native Iran to Italy, England, Sweden and the United States, Dr. Naeimi Kararoudi has collected…

read more
Optimizing the Body’s Natural Cancer Killers
 Optimizing the Body’s Natural Cancer Killers 1024 649 Katie Brind'Amour, PhD, MS, CHES
By:

Recent advances in the expansion and production of natural killer cells offers pediatric patients new hope for remission after high-risk cancer diagnoses. Natural killer (NK) cells are the innate immune system’s first line of defense for viral infections. Although these white blood cells don’t have the antigen-specific “memory” that characterizes T cells or the antibody-producing…

read more
Therapy With Double-Bright Natural Killer Cell Infusions Increases Response Rates Among Frail Patients With Acute Myeloid Leukemia
 Therapy With Double-Bright Natural Killer Cell Infusions Increases Response Rates Among Frail Patients With Acute Myeloid Leukemia 969 533 Jessica Nye, PhD
By:
Illustration of NK Cells, T Cells, other immune cells floating across white background

A case series of 13 patients with relapsed/refractory acute myeloid leukemia (AML) finds that a novel approach using repeated infusions of cultured natural killer (NK) cells increases overall and complete response rates. NK cells are lymphocytes – white blood cell components of the innate immune response – that have anti-leukemic properties. Although efforts to incorporate…

read more
Administering NK Cells Post-Transplant Improves Relapse in Myeloid Malignancies
 Administering NK Cells Post-Transplant Improves Relapse in Myeloid Malignancies 150 150 Mary Bates, PhD
By:

A Phase I/II clinical trial demonstrates donor-derived NK cells are safe and effective at decreasing relapse and increasing survival in adults with myeloid malignancies. Haploidentical stem-cell transplantation can be a successful treatment for patients with myeloid malignancies, but relapse remains a common risk. Natural killer (NK) cells are a subset of lymphocytes capable of recognizing…

read more